Current treatment options for autoimmune disease (AID) are essentially immunosuppressive, inhibiting the inflammatory cascade, without curing the disease. Therapeutic monoclonal antibodies (mAbs) that target B cells showed efficacy, emphasizing the importance of B lymphocytes in autoimmune pathogenesis. Treatments that eliminate more potently B cells would open a new therapeutic era for AID. Immune cells can now be bioengineered to express constructs that enable them to specifically eradicate pathogenic B lymphocytes. Engineered immune cells (EICs) have shown therapeutic promise in both experimental models and in clinical trials in AID. Next-generation platforms are under development to optimize their specificity and improve safety. The profound and durable B cell depletion achieved reinforces the view that this biotherapeutic option holds promise for treating AID.

中文翻译：

---

工程免疫细胞作为自身免疫性疾病的治疗方法


目前自身免疫性疾病 (AID) 的治疗方案基本上是免疫抑制，抑制炎症级联反应，但无法治愈疾病。针对 B 细胞的治疗性单克隆抗体 (mAb) 显示出功效，强调了 B 淋巴细胞在自身免疫发病机制中的重要性。更有效地消除 B 细胞的治疗将为 AID 开启一个新的治疗时代。现在可以对免疫细胞进行生物工程改造，使其表达能够特异性消除致病性 B 淋巴细胞的结构。工程免疫细胞 (EIC) 在 AID 的实验模型和临床试验中都显示出治疗前景。下一代平台正在开发中，以优化其特异性并提高安全性。所实现的深度和持久的 B 细胞耗竭强化了这样的观点：这种生物治疗选择有望治疗艾滋病。